首页> 美国卫生研究院文献>Cell Discovery >Author Correction: Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension

【2h】

Author Correction: Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension

机译：作者校正：钙通道阻滞剂氨氯氨脒苯磺酸盐治疗与Covid-19患者的高血压患者的病例降低有关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

These authors contributed equally: Lei-Ke Zhang, Yuan Sun, Haolong Zeng, Qingxing Wang.

机译：these authors contributed equally: lei-KE Zhang, yuan sun, H傲龙Zen G, Qing兴Wang.

著录项

期刊名称 Cell Discovery
作者
Lei-Ke Zhang; Yuan Sun; Haolong Zeng; Qingxing Wang; Xiaming Jiang; Wei-Juan Shang; Yan Wu; Shufen Li; Yu-Lan Zhang; Zhao-Nian Hao; Hongbo Chen; Runming Jin; Wei Liu; Hao Li; Ke Peng; Gengfu Xiao;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 1
原文格式 PDF
正文语种
中图分类
关键词
Mechanisms of disease; Cell biology;

机译：疾病机制;细胞生物学;

相似文献

外文文献
中文文献
专利

1. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intende [J] . Iino Y, Hayashi M, Kawamura T, Clinical and experimental nephrology . 2003,第3期

机译：血管紧张素II受体拮抗剂洛沙坦与钙通道阻滞剂氨氯地平在慢性肾脏疾病和高血压患者中的肾脏保护作用的临时证据：日本氯沙坦治疗方案的报告
2. In vitro Binding Chemistry of Amlodipine Besylate (Calcium Channel Blocker) and Atorvastatin Calcium (HMG-CoA Reductase Inhibitor) to Serum Albumin and their Mutual Effect to Displace Each Other from the Binding Site [J] . K.D. Alam, M.K. Hosain, S. Kabir, American Journal of Drug Discovery and Development . 2011,第4期

机译：苯磺酸氨氯地平（钙通道阻滞剂）和阿托伐他汀钙（HMG-CoA还原酶抑制剂）与血清白蛋白的体外结合化学及其从结合位点相互置换的相互作用
3. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. [J] . Hilleman DE, Reyes AP, Wurdeman RL, Journal of human hypertension . 2001,第8期

机译：从高剂量钙通道阻滞剂到氨氯地平/贝那普利固定剂量联合用药的治疗性互换治疗中重度高血压的疗效和安全性。
4. Dynamic non-linear changes in heart rate variability in patients with coronary heart disease and arterial hypertension treated by amlodipine besylate [C] . Krstacic, G., Krstacic, . 2003

机译：苯磺酸氨氯地平治疗冠心病和动脉高血压患者心率变异性的动态非线性变化
5. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension [O] . Lei-Ke Zhang, Yuan Sun, Haolong Zeng, 2020

机译：钙通道阻滞剂氨氯地平苯磺酸盐治疗与Covid-19患者的高血压患者的病例降低有关
6. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension [O] . DE Hilleman, AP Reyes, RL Wurdeman, 2001

机译：治疗性交换的疗效和安全性与高剂量钙通道阻滞剂对中度至严重的高血压患者的氨氯普琳/苯那普里尔的固定剂量组合
7. Evaluation of Beta-Blockers, Calcium Antagonists. Nitrates, and Alternative211 Therapies for Stable Angina. Evidence Report/Technology Assessment No. 10 [R] . Heidenreich, P. A., McDonald, K. M., Hastie, T., 1999

机译：评估β-受体阻滞剂，钙拮抗剂。硝酸盐和稳定心绞痛的alternative211治疗。证据报告/技术评估第10号

Author Correction: Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension

摘要

著录项

相似文献

相关主题

期刊订阅